SCHEMBL5437861

SCHEMBL5437861

C=Cc1cnc(Nc2ccc(S(=O)(=O)CCCN3CCCC3)cc2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 8/20 0.48
ABL1 P00519 3/20 0.46
PDGFRB P09619 2/20 0.45
CDK2 P24941 2/20 0.45
CDK4 P11802 2/20 0.45
LOX P28300 1/20 0.43
EPHX2 P34913 2/20 0.42
AURKA O14965 2/20 0.38
CDK1 P06493 1/20 0.38
CCNB1 P14635 1/20 0.38
HRH3 Q9Y5N1 3/20 0.37
BRD4 O60885 2/20 0.37
BMPR1B O00238 1/20 0.37
PLK4 O00444 1/20 0.37
STK25 O00506 1/20 0.37
CIT O14578 1/20 0.37
RIOK3 O14730 1/20 0.37
CHEK1 O14757 1/20 0.37
IKBKB O14920 1/20 0.37
CASK O14936 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2492457 0.86 SRC (0.49) SRCABL1PDGFRBCDK2CDK4
SCHEMBL5440594 0.82 SIGMAR1 (0.54) SRCPDGFRBYES1EPHB4NEK1
SCHEMBL14501662 0.78 AXL (0.53) AXLMERTK
SCHEMBL5442293 0.77 SRC (0.45) SRCABL1PDGFRBCDK2CDK4
SCHEMBL5445567 0.77 SRC (0.43) SRCABL1PDGFRBCDK2CDK4
SCHEMBL5445574 0.77 SRC (0.43) SRCABL1PDGFRBCDK2CDK4
SCHEMBL5443806 0.77 SRC (0.44) SRCABL1PDGFRBCDK2CDK4
SCHEMBL5443809 0.77 SRC (0.44) SRCABL1PDGFRBCDK2CDK4
SCHEMBL5442287 0.77 SRC (0.45) SRCABL1PDGFRBCDK2CDK4
SCHEMBL5998026 0.76 LCK (0.57) SRCABL1PDGFRBCDK2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations TARGEGEN, INC. (US) 2007-06-28 US disclosed
WO-2007056075-A2 SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS TARGEGEN, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149508-A1 Six membered heteroaromatic inhibitors targeting resistant kinase mutations ABL1, KDR, BCR SRC 71/4885ABL1 1/4885PDGFRB 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.